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Association between bisphosphonate therapy and outcomes from 1 
rehabilitation in older people 2 
 3 
Abstract 4 
Background 5 
Bisphosphonate therapy may have actions beyond bone, including effects on cardiovascular, 6 
immune and muscle function. We tested whether bisphosphonate treatment is associated with 7 
improved outcomes in older people undergoing inpatient rehabilitation 8 
 9 
Methods 10 
Analysis of prospectively collected, linked routine clinical datasets. Participants were divided 11 
into never users of bisphosphonates, use prior to rehabilitation only, use after rehabilitation 12 
only, and current users (use before and after rehabilitation). We calculated change in 20-point 13 
Barthel scores during rehabilitation, adjusting for comorbid disease and laboratory data using 14 
multivariable regression analysis. Cox regression analyses were performed to analyse the 15 
association between bisphosphonate use and time to death or hospitalisation. 16 
 17 
Results 18 
2797 patients were included in the analysis. Current bisphosphonate users showed greater 19 
improvement in Barthel score during rehabilitation than non-users (5.0 points [95%CI 4.3 to 20 
5.7] vs 3.8 [95%CI 3.6 to 3.9]), but no difference compared to those receiving bisphosphonates 21 
only after discharge (5.1 [95%CI 4.6 to 5.5]). Previous bisphosphonate use was significantly 22 
associated with time to death (adjusted hazard ratio 1.41 [95%CI 1.15 to 1.73]) but less strongly 23 
with time to combined endpoint of hospitalisation or death (adjusted hazard ratio 1.18 [95%CI 24 
0.98 to 1.48]). Use after discharge from rehabilitation was associated with reduced risk of death 25 
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(adjusted hazard ratio 0.64 [95%CI 0.55 to 0.73]; hazard ratio per year of bisphosphonate 26 
prescription 0.98 [95%CI 0.97 to 0.99]) 27 
 28 
Conclusion 29 
Bisphosphonate use is unlikely to be causally associated with improved physical function in 30 
older people, but continuing use may be associated with lower risk of death. 31 
 32 
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 35 
Introduction 36 
 37 
Bisphosphonates are widely used as antiresorptive agents for treating osteoporosis. They bind 38 
to bone with high affinity, impairing the ability of osteoclasts to adhere to and resorb bone; 39 
they also promote apoptosis of osteoclasts, impair maturation of osteoclast progenitors, and 40 
hence reduce bone turnover and resorption. The consequent increase in bone mineral density 41 
reduces the relative risk of post-menopausal osteoporotic fractures by between 30 and 70%1. 42 
In addition, bisphosphonate therapy may have effects beyond reducing fracture rates; in a 43 
recent meta-analysis, bisphosphonate therapy reduced all-cause mortality by 10% in high-risk 44 
groups, an effect that appears much greater than can be attributed solely to their effect on 45 
fracture reduction2,3. Furthermore, the reduction in all-cause mortality is not driven by 46 
reductions in specific major event groups (e.g. cardiovascular events, cancer or infection) but 47 
appears to be distributed across multiple causes of death4.    48 
 49 
Bisphosphonates have been shown to display a number of pleiotropic biological effects that 50 
might contribute to the above findings. First, nitrogen-containing bisphosphonates may exhibit 51 
actions on lipid metabolism similar to statin medications, via inhibition of the mevalonate 52 
pathway, thereby reducing the progression of atherogenic processes5-8. Statins themselves have 53 
been associated with improved outcomes from rehabilitation9,10. Related effects on the 54 
mevalonate pathway underlie alterations to lipid anchoring of a number of intracellular 55 
signalling molecules, which may explain the anticancer effects of bisphosphonates therapy 56 
observed in some studies. Effects on reducing oxidative stress have also been postulated; 57 
oxidative stress in turn has been linked to a wide range of disease states including 58 
cardiovascular disease11, cancer, and sarcopenia - the age-related loss of muscle mass and 59 
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strength12,13. Bisphosphonates may also initially promote low-grade, chronic inflammation (via 60 
production of pro-inflammatory cytokines14,15) which in turn may activate protective 61 
mechanisms at a cellular level which protect against the consequences of more severe 62 
inflammation.  Finally, recent preclinical data suggests that zoledronate can protect 63 
mesenchymal stem cells against the accumulation of DNA damage16. 64 
 65 
Rehabilitation is an essential step on the pathway back to independent function for older people 66 
who have suffered intercurrent illness. Whilst it is recognised that rehabilitation is dependent 67 
on a number of factors, not least the quality and input of an exercise programme, it can be 68 
interrupted by further intercurrent illness with a consequent vicious cycle of immobility, 69 
worsening physical function and increased susceptibility to illness. Rehabilitation may also 70 
progress slowly due to intrinsic pathophysiological limitations like sarcopenia. Successful 71 
rehabilitation in older people might thus be enhanced by agents with pleiotropic effects on a 72 
variety of biological pathways to improve resilience; agents that improve muscle function 73 
directly would clearly be useful, but agents that either reduce intercurrent illness or mitigate 74 
the effects of intercurrent illness may also be of benefit. We therefore tested whether 75 
bisphosphonate treatment was associated with improved outcomes in a large cohort of older 76 
people undergoing inpatient rehabilitation, using routinely collected health and functional data.  77 
 78 
Methods 79 
Data Sources and Patient Population 80 
This study was performed as part of a data linkage project which combined detailed healthcare 81 
data held on residents of Tayside, Scotland, held by the University of Dundee Health 82 
Informatics Centre (HIC) with functional outcome data on older people who had undergone 83 
inpatient rehabilitation within the Dundee Medicine for the Elderly service (DOME). Data 84 
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linkage was achieved using the Community Health Index (CHI), a unique healthcare identifier 85 
assigned to all Scottish healthcare users. Data linkage was carried out by HIC, with the 86 
combined, anonymised dataset hosted in a safe haven facility, which allows analysis by 87 
permitted parties without release of raw data outside the safe haven facility. 88 
 89 
The DOME functional outcome data forming the basis of this analysis has been described 90 
previously17,18. We used an extended version of this dataset, which was collected prospectively 91 
on all patients admitted for rehabilitation over a 13 year period between 1st January 1999 and 92 
31st December 2011, and comprised approximately 5500 admissions on 4382 individuals. The 93 
HIC database is a comprehensive set of health data on 400,000 people within the Tayside, 94 
Scotland area. In this study, health data was extracted from the HIC database for those patients 95 
registered on the DOME database. Prescribing information, biochemistry and haematology 96 
results, hospitalization data and diagnoses (Scottish Morbidity Register 01) coded using ICD-97 
10 codes were available. Data on date of death was obtained via the Scottish Government 98 
Records Office, which records all deaths registered in Scotland. For this analysis, the cohort 99 
consisted of patients undergoing their first admission to the rehabilitation service, and omitted 100 
repeat admissions to the rehabilitation service, so that effects of previous rehabilitation did not 101 
impact on either baseline function or response to rehabilitation. 102 
  103 
Bisphosphonate use 104 
Bisphosphonate use was defined by extracting prescription records for bisphosphonate 105 
medications contained in the British National Formulary. All bisphosphonates used in the study 106 
population were included, namely alendronate, risedronate, etidronate, clodronate and 107 
ibandronate. Zoledronic acid was not used within the service covered by this cohort during the 108 
time period under study. Data on prescribing are held only for prescriptions dispensed in the 109 
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community, not in hospital; no electronic record exists for in-hospital prescriptions. We thus 110 
used community prescribing data from before and after each inpatient rehabilitation period to 111 
categorise patients into four groups: Current users comprised patients who were prescribed 112 
bisphosphonates at any time during the six months immediately prior and at any time in the 6 113 
months subsequent to rehabilitation. Previous users comprised patients prescribed 114 
bisphosphonates in the two year period prior to rehabilitation, excluding those in group A. 115 
Subsequent users comprised patients who received bisphosphonates only after discharge from 116 
rehabilitation, and did not receive bisphosphonates in the two years prior to admission. Never 117 
users consisted of patients with no prescription for bisphosphonates recorded either before or 118 
after the rehabilitation stay at any point covered by the database (dating back to 01/01/1998 119 
and censored at 04/05/2012). This approach allowed us to dissect out whether changes 120 
associated with bisphosphonate use were likely to be due to bisphosphonates, or due to 121 
unmeasured characteristics of patients who were more likely to be prescribed bisphosphonates. 122 
Relatively wide time windows were employed in part due to the known long duration of action 123 
of bisphosphonate medications, and because prescriptions for bisphosphonates are renewed 124 
infrequently due to the weekly dosing of many preparations.  125 
 126 
 127 
Measurement of functional status 128 
The functional outcome utilised in this study was the 20 point Barthel Index19, a widely used 129 
and validated measure of patients’ abilities in activities of daily living. The Barthel index 130 
consists of 10 separate function categories each with possible scores of 0/1, 0/1/2, or 0/1/2/3, 131 
yielding a total score out of 20, with a higher score indicating greater independence. A Barthel 132 
score was recorded by rehabilitation staff at admission and at discharge from inpatient 133 
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rehabilitation. Discharge destination (coded as return to own home or elsewhere) was obtained 134 
from the rehabilitation dataset. 135 
 136 
Comorbidities and other covariates 137 
Covariates were selected on the basis of clinical plausibility and prior knowledge, based on 138 
their likelihood to interact with bisphosphonate therapy, affect rehabilitation outcome, physical 139 
function or susceptibility to illness. Age and sex were obtained from healthcare demographic 140 
information held within HIC data. Previous hospitalisation for myocardial infarction, stroke, 141 
COPD and heart failure were coded from ICD-10 codes held in HIC healthcare data. Previous 142 
diagnoses of cancer were obtained from SMR06 (Scottish Cancer Registry) data, and previous 143 
diagnoses of diabetes mellitus were obtained from the Scottish Care Information - Diabetes 144 
Collaboration (SCI-DC) database, which records all diagnoses of diabetes within Scotland. 145 
Renal function (recorded as estimated glomerular filtration rate [eGFR] and calculated by the 146 
Modified Diet in Renal Disease [MRDR4] equation20, serum calcium and serum albumin 147 
values were extracted from routinely collected biochemistry data held in HIC; the value closest 148 
to the date of admission to rehabilitation was used. Prescribed calcium and vitamin D 149 
supplementation was assessed by extraction of prescribing data in a similar way to 150 
bisphosphonate medication. 151 
 152 
Data Analysis 153 
Data analyses were performed using SPSS v21 (IBM, New York, USA) or SAS v9.2 (SAS 154 
Institute Inc., Cary, NC, USA). Patients who died during admission or had a missing admission 155 
or discharge Barthel score were excluded from analysis. Where patients had had multiple 156 
admissions to the rehabilitation service, only the first admission was included in the analysis, 157 
and subsequent admissions were ignored. Baseline factors were compared by bisphosphonate 158 
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use, using one-way ANOVA for normally distributed continuous variables, Kruskal-Wallis test 159 
for non-normally distributed continuous variables, and Pearson’s Chi-squared test for 160 
categorical variables. The association between bisphosphonate use and improvement in Barthel 161 
score during rehabilitation was assessed by multivariable regression analysis, adjusting for age, 162 
sex, admission Barthel score, calcium/vitamin D use, renal function (eGFR), albumin, 163 
corrected calcium, previous diagnosis of diabetes mellitus, previous indication of IHD, stroke, 164 
cancer, COPD and CHF, and number of prescribed medications. A sensitivity analysis was 165 
conducted excluding those patients who had received non-aminobisphosphonates (clodronate 166 
or etidronate) due to their lack of effect on the mevalonate pathway. Because calcium and 167 
vitamin D are almost always co-administered with bisphosphonates, we analysed whether 168 
calcium and vitamin D use was associated with differences in rehabilitation outcomes, death 169 
or time to hospitalisation in the group of patients who had never taken bisphosphonates; if a 170 
significant effect were to be evident, the results of analyses of bisphosphonate exposure would 171 
not be reliably attributable to bisphosphonates. For those taking bisphosphonates prior to 172 
rehabilitation, the number of days of exposure in the year prior to rehabilitation was calculated 173 
– those on weekly preparations counted as 7 days per exposure, those on monthly preparations 174 
counted as 30 days per exposure. Adherence, which is known to be suboptimal with oral 175 
bisphosphonates, could not be directly calculated as data on encashed prescriptions was 176 
available, but date of decision to commence prescribing was not. 177 
 178 
We conducted Cox regression analyses to estimate the association between bisphosphonate use 179 
and time to death after discharge from rehabilitation; similar analyses were conducted for time 180 
to a combined endpoint of death or next hospitalisation. For each analysis, models were run 181 
both unadjusted and adjusted for the variables listed above including discharge destination. 182 
Models were run comparing each of the groups against those patients never using 183 
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bisphosphonates. To separate out the effect of previous exposure to bisphosphonates (which 184 
might be a marker for unmeasured frailty or comorbidity) from the effect of subsequent use, a 185 
separate analysis was run using any use prior to rehabilitation as a distinct variable from any 186 
use after discharge from rehabilitation. Further analyses were run using time-dependent Cox 187 
regression analyses; the cumulative exposure to bisphosphonates post-discharge was included 188 
as a time-dependent variable, with pre-admission exposure included as a categorical variable 189 
and other adjusting variables included as listed above. 190 
  191 
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 192 
Results 193 
Data were available on 4382 first admissions to rehabilitation. 95 patients were omitted from 194 
the analysis because they had last received bisphosphonates greater than 2 years prior to 195 
admission. 366 patients died during their rehabilitation stay (27/392 [6.9%] of previous 196 
bisphosphonate users versus 339/3895 (8.7%) of never users, p=0.22). Of the remainder of the 197 
cohort, 1124 patients were excluded due to missing admission or discharge Barthel data. 198 
Analyses were therefore conducted on the remaining 2797 patients. Table 1 gives the baseline 199 
details for the four analysis groups.  200 
 201 
No effect of calcium and vitamin D supplementation was evident on either rehabilitation 202 
outcomes (3.8 points vs 3.7 points improvement during rehabilitation, p=0.15), risk of death 203 
(hazard ratio 0.90, 95%CI 0.72 to 1.12), or risk of hospitalisation or death (hazard ratio 0.99, 204 
95%CI 0.81 to 1.21) in the group of patients who had never used bisphosphonates. Calcium 205 
and vitamin D use was included as a covariate in all subsequent analyses. Table 2 shows the 206 
association between different patterns of bisphosphonate exposure and improvements seen in 207 
Barthel score during inpatient rehabilitation, giving both unadjusted results and results adjusted 208 
for the variables listed above. Excluding those patients who had used non-nitrogen-containing 209 
bisphosphonates (clodronate or etidronate) did not significantly change the results (adjusted 210 
improvement in Barthel scores for never, previous, current and subsequent users: 3.8 [3.6 to 211 
3.9]; 3.7 [2.9 to 4.5]; 5.8 [4.9 to 6.6]; 5.1 [4.6 to 5.5]; p=0.17 for current vs subsequent users). 212 
Exposure to bisphosphonates in the year prior to rehabilitation varied, with 43% of those taking 213 
bisphosphonates prior to rehabilitation taking less than 180 days equivalent in the year prior to 214 
admission. However there was no significant correlation between the number of days of 215 
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bisphosphonate use in the year prior to rehabilitation and the improvement in Barthel score 216 
(unadjusted r=-0.05, p=0.49; adjusted r=-0.12, p=0.15)  217 
 218 
Table 3 gives the results of both unadjusted and adjusted Cox regression analyses, showing the 219 
effect of exposure to bisphosphonates post-discharge on both survival and time to the combined 220 
death or next hospitalisation endpoint. Time-dependent Cox regression analyses showed 221 
similar results; the adjusted hazard ratio for death post-discharge was 0.98 (95%CI 0.97 to 222 
0.99) per year of post-discharge bisphosphonate exposure, and the adjusted hazard ratio for 223 
death or next hospitalisation post-discharge was 1.01 (95%CI 0.98 to 1.04) per year of post-224 
discharge bisphosphonate exposure.  225 
 226 
 227 
Discussion 228 
The results from this analysis do not support a beneficial effect of bisphosphonate use on 229 
physical function outcomes in rehabilitation, as measured by the Barthel score. Although 230 
current bisphosphonate users achieved greater improvement in function during rehabilitation 231 
compared to previous users and never users, current users showed similar improvements to 232 
those who used bisphosphonates only after discharge from rehabilitation. For this latter group, 233 
drug exposure occurred only after discharge from rehabilitation and thus their functional 234 
improvement cannot be attributed to the effects of bisphosphonates. Our results do not 235 
therefore support a causal association between bisphosphonate therapy and functional 236 
improvement in this cohort. For post-discharge time to death and to next hospitalisation, our 237 
results suggest that previous exposure to bisphosphonates is a marker of increased risk of death 238 
or hospitalisation, but that ongoing exposure to bisphosphonates is associated with reduced 239 
hazard of death, and a less significant reduction in hazard of hospitalisation. 240 
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 241 
To our knowledge, this is the first study to examine the relationship between bisphosphonate 242 
use and functional outcomes during rehabilitation. The results of our analyses do not suggest a 243 
biological effect of bisphosphonates on biological pathways that might improve performance 244 
during rehabilitation – either via direct effects on musculoskeletal function or by reducing 245 
adverse events that interrupt rehabilitation. Rather, the results are consistent with current and 246 
future bisphosphonate use being a marker for unmeasured patient characteristics that are 247 
associated with better rehabilitation outcomes. Fitter, more robust patients who are perceived 248 
as having more to gain and longer to live may be more likely to be given bisphosphonates, and 249 
although the Barthel scores at admission to rehabilitation were similar across all four groups, 250 
there are other aspects of physical function and frailty that we were unable to measure directly 251 
using this routinely collected dataset. 252 
 253 
A further potential confounder to address in this context is the frequent co-administration of 254 
calcium and vitamin D in routine treatment with bisphosphonates. UK clinical guidelines state 255 
that clinicians should ensure patients have an adequate intake of calcium and are vitamin D 256 
replete before prescribing bisphosphonates. The majority of older, frail patients in Scotland 257 
have low 25-hydroxyvitamin D levels – and our cohort are even more likely to have low levels 258 
given their prolonged stay in hospital. In the absence of vitamin D repletion, the increases in 259 
bone mineral density and anti-fracture efficacy associated with bisphosphonates, are 260 
attenuated21. Vitamin D has a direct effect on muscle function22, and therefore supplementation 261 
with this agent could confound the association between bisphosphonates and functional 262 
outcomes. We did not have data on 25-hydroxyvitamin D levels for this cohort, and thus we 263 
cannot completely adjust for the effect that vitamin D repletion might have had on the analyses. 264 
However, analysis of the large group of patients who had never received a bisphosphonate did 265 
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not support an effect of calcium and vitamin D on either rehabilitation outcomes, survival or 266 
hospitalisation in this group, making this explanation less likely. 267 
 268 
The results from analysis of time to death are broadly consistent with other randomised trial 269 
and observational data3,4,23,24 suggesting that bisphosphonates are associated with a lower risk 270 
of death. This is despite the fact that previous bisphosphonate use appears to be a risk marker 271 
for higher rates of death and hospitalisation. Such a finding, whilst paradoxical at first sight, is 272 
consistent with the fact that bisphosphonates will typically be used in those with a disease 273 
(osteoporosis) with major adverse consequences on fitness and function, which is itself 274 
associated with other life-shortening disease complexes (particularly cardiovascular 275 
disease5,25). Thus being prescribed bisphosphonates at some previous time may be a marker of 276 
a group at increased risk of death, but greater exposure to bisphosphonates themselves could 277 
still confer protective effects. Less striking results were seen on analysing time to 278 
hospitalisation or death; some previous studies have suggested lower death rates with 279 
bisphosphonate use, but not lower event rates for vascular disease. This would be consistent 280 
with our findings, and one possibility is that bisphosphonates might not reduce event rates, but 281 
might reduce the severity or impact of events on homeostatic function – i.e. they might enhance 282 
biological resilience26 via yet to be determined mechanisms. It is noteworthy that the more 283 
potent bisphosphonates are known to induce an acute-phase inflammatory response in some 284 
users2; inflammatory responses are also thought to contribute to the pathophysiology 285 
underlying phenomena such as ischaemic preconditioning in different organ systems27,28. 286 
Another possible mechanism is via anti-apoptotic effects; although bisphosphonates promote 287 
apoptosis of osteoclasts, they inhibit apoptosis of osteoblasts and osteoclasts, possibly via 288 
effects on pathways linked to connexin 43 29,30. Similar pathways are present in other tissues, 289 
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including cardiomyocytes31, although the actions of bisphosphonates on apoptosis in human 290 
organ systems outwith bone remain to be elucidated. 291 
 292 
Our study had a number of significant strengths. The dataset combined detailed health and 293 
functional outcomes data on a large set of patients undergoing rehabilitation in the real world, 294 
which enhances the generalisability of the data. Use of prescribing data from both before and 295 
after rehabilitation allowed us to test causal relationships in a way that would not have been 296 
possible without post-discharge prescribing data; these data enabled a more robust schema to 297 
be used to determine bisphosphonate treatment level (including use up to two years prior to 298 
rehabilitation and subsequent use), as opposed to a simple dichotomous indicator of treatment 299 
or no treatment at admission. Furthermore, the prescribing data comprises prescriptions 300 
encashed by patients and dispensed by pharmacists, rather than merely prescriptions written by 301 
physicians, thus the prescribing data may better reflect medication adherence than measures 302 
based on analysing numbers of prescriptions written. Combining detailed biochemical data 303 
allowed us to adjust analyses for albumin and renal function, both of which are important 304 
potential confounders.  305 
 306 
A number of weaknesses deserve comment. The use of routine data limits the type of measures 307 
of frailty and function to those available from clinical practice when the data were collected, 308 
and missing data are frequent. Adherence was not measured directly; although prescriptions 309 
were dispensed we have no measure of ingestion of medication. Furthermore, we cannot 310 
account for medications available without prescription, which included low-dose calcium and 311 
vitamin D. Although intravenous bisphosphonates such as ibandronate and zoledronate were 312 
not used within our service (which included osteoporosis management) during the time period 313 
studied, we cannot exclude the possibility that a few patients received courses of intravenous 314 
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bisphosphonates (e.g. to treat hypercalcaemia of malignancy) via oncology or other services; 315 
community prescribing data does not capture this use. We did not attempt to distinguish 316 
between different types of bisphosphonate; the majority of patients took once-weekly oral 317 
bisphosphonates. Although there may be different effects between different agents, the effects 318 
on mortality from trials appear to be broadly consistent in meta-analysis3. A further potential 319 
limitation is that we did not have access to 25-hydroxyvitamin D or PTH levels on patients; we 320 
are therefore unable to test whether vitamin D insufficiency or secondary hyperparathyroidism 321 
might modify the results of our analysis.  322 
 323 
Bisphosphonates have a long duration of action on bone32, in part because they bind to 324 
hydroxyapatite crystals. The time course of biological effects in other organ systems is less 325 
clear33; our analysis assumes an extended duration of action after dosing, but this may not be 326 
the case for all potential biological effects. Similarly, the effects of bisphosphonates in this 327 
analysis are difficult to fully separate from any effects of calcium and vitamin D, both of which 328 
are known to have pleiotropic biological effects across multiple organ systems22. Finally, the 329 
cohort that we used comprised older patients selected for inpatient rehabilitation, and the cohort 330 
was exclusively white and mostly Northern European in ancestry. The findings from this cohort 331 
are not therefore necessarily generalizable to cohort comprising younger, fitter patients, 332 
unselected older patients or patients with different racial or ethnic background.  333 
 334 
Our work suggests a number of avenues for future research. Replication of these findings in 335 
other cohorts would be of interest to ensure that an effect has not been missed by our analysis. 336 
Although the lack of evidence for a causal relationship between bisphosphonate use and 337 
improved rehabilitation outcomes does not support conducting trials in this specific area, the 338 
idea that bisphosphonates might be able to reduce death rates in older people by mitigating the 339 
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deleterious impact of health events is an intriguing one, which merits further study. Studies 340 
designed specifically to examine this idea are needed, and should not be confined to patients 341 
with osteoporosis; both studies to explore possible biological mechanisms for the lower 342 
mortality seen in bisphosphonate users, and studies to test whether such an effect can be 343 
reproduced in those without osteoporosis, would be of considerable interest. 344 
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Table 1. Baseline Details (n=2797) 438 
 439 
 Never used Previous use Current use Subsequent use 
N (%) 2351 (84) 124 (4) 95 (3) 227 (8) 
Mean age (SD) 84.2 (7.6) 83.3 (6.9) 84.7 (6.3) 83.7 (7) 
Male sex (%) 1056 (45) 24 (19) 15 (16) 58 (26) 
Median length of stay (IQR) 36 (46) 33 (44) 35 (46) 38 (40) 
Previous myocardial infarction (%) 533 (23) 38 (31) 33 (35) 41 (18) 
Previous stroke (%) 533 (23) 17 (14) 17 (18) 41 (18) 
Previous heart failure (%) 370 (16) 22 (18) 14 (15) 14 (6) 
Previous hip fracture (%) 188 (8) 10 (8) 11 (12) 47 (21) 
Previous COPD (%) 299 (13) 33 (27) 20 (21) 27 (12) 
23 
 
Previous diagnosis of cancer (%) 290 (12) 18 (15) 7 (7) 25 (11) 
Diabetes mellitus (%) 418 (18) 20 (16) 11 (12) 37 (16) 
Mean admission Barthel score (SD) 10.4 (3.9) 10.9 (3.4) 10.5 (3) 10.9 (3.2) 
Median no of medications at admission (IQR) 2 (5) 3 (6) 7 (4) 2 (3) 
Discharged to own home (%) 1743 (74) 97 (78) 87 (92) 202 (89) 
Mean adjusted serum calcium (mmol/L) (SD) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1) 
Mean eGFR (ml/min) (SD) 61.2 (23.7) 68 (31.5) 64.5 (28.2) 65.2 (23.2) 
Mean haemoglobin (g/dL) (SD) 12.1 (1.9) 11.7 (1.8) 11.9 (2.2) 11.8 (1.8) 
Mean albumin (g/L) (SD) 36.7 (4.9) 36.0 (4.6) 37.5 (4.5) 36.9 (4.9) 
 440 
  441 
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Table 2. Association between Bisphosphonate use and change in Barthel Score during Rehabilitation 442 
 443 
 Never used Previous use Current use Subsequent use 
Unadjusted change in Barthel score (95% CI) 3.8  
(3.6-3.9) 
3.4  
(2.8-4.0) 
5.2** 
(4.6-5.9) 
5.0**  
(4.6-5.5) 
Adjusted change in Barthel score (95% CI) 3.8  
(3.6-3.9) 
3.4  
(2.8-4.0) 
5.0 ** 
(4.3-5.7) 
5.1**  
(4.6-5.5) 
Unadjusted length of stay (95% CI) (days) 57  
(54.6-59) 
46 
(36-57) 
51  
(39-63) 
54 
(47-62) 
Adjusted length of stay (95% CI) (days) 56  
(54-58) 
50 
(40-59) 
62  
(50-73) 
54 
(47-61) 
 444 
*P<.05, **P<.001 vs never users 445 
Adjusted for: Baseline Barthel score, age, sex, comorbid disease (myocardial infarction, stroke, heart failure, chronic obstructive pulmonary disease, diabetes 446 
mellitus, previous cancer), medication burden, recent hip fracture, baseline albumin, calcium, renal function (eGFR), and haemoglobin 447 
Barthel score range 0 to 20; higher values indicate better function 448 
  449 
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Table 3. Cox Regression Analysis for Time to Death or next Hospitalisation 450 
 Never used 
(n=2459) 
Previous use 
(n=133) 
Current use 
(n=100) 
Subsequent use only 
(n=237) 
Unadjusted hazard ratio for death (95% CI) 1 1.39 (1.13 to 1.69) 0.79 (0.62 to 1.00) 0.50 (0.43 to 0.60) 
Adjusted hazard ratio for death (95% CI) 1 1.41 (1.15 to 1.73) 1.00 (0.77 to 1.29) 0.57 (0.48 to 0.67) 
Unadjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1 1.21 (1.00 to 1.45) 1.20 (0.98 to 1.47) 0.81 (0.71 to 0.93) 
Adjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1 1.18 (0.98 to 1.48) 1.27 (1.01 to 1.59) 0.88 (0.77 to 1.02) 
 Previous use vs no previous use Use post-discharge vs no use post-discharge 
Unadjusted hazard ratio for death (95% CI) 1.13 (0.97 to 1.32) 0.56 (0.48 vs 0.65) 
Adjusted hazard ratio for death (95% CI) 1.32 (1.11 to 1.56) 0.64 (0.55 to 0.73) 
Unadjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1.23 (1.07 to 1.41) 0.89 (0.79 to 1.00) 
Adjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1.24 (1.06 to 1.44) 0.95 (0.84 to 1.08) 
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